A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

NCT06198712 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Etavopivat

Sponsor

Forma Therapeutics, Inc.

Collaborators

[object Object]